NMRA (Neumora Therapeutics) Short Interest

View and export this data going back to 2023. Start your Free Trial

What is Neumora Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Neumora Therapeutics's Short Interest

For the Biotechnology subindustry, Neumora Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neumora Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's Short Interest falls into.

Save Embed

;

Save Embed

;

Neumora Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472

Website

https://www.neumoratx.com

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Executives

Michael Lee Milligan	officer: See Remarks	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Robert A. Lenz	officer: Head of R&D	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Paul L Berns	director	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Joshua Pinto	officer: Chief Financial Officer	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Daljit Singh Aurora	officer: Chief Strategy Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, Llc	10 percent owner	8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Amgen Inc	10 percent owner	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Henry O Gosebruch	director, officer: President & CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Arch Venture Fund Xii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, L.p.	10 percent owner	8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Alaa Halawa	director	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472